INmune Bio (INMB) Competitors $2.36 +0.27 (+12.92%) Closing price 04:00 PM EasternExtended Trading$2.22 -0.15 (-6.14%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock INMB vs. ALT, CDTX, KROS, RLAY, DNTH, ARVN, MRVI, TSHA, OPT, and TYRAShould you be buying INmune Bio stock or one of its competitors? The main competitors of INmune Bio include Altimmune (ALT), Cidara Therapeutics (CDTX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), Dianthus Therapeutics (DNTH), Arvinas (ARVN), Maravai LifeSciences (MRVI), Taysha Gene Therapies (TSHA), Opthea (OPT), and Tyra Biosciences (TYRA). These companies are all part of the "pharmaceutical products" industry. INmune Bio vs. Its Competitors Altimmune Cidara Therapeutics Keros Therapeutics Relay Therapeutics Dianthus Therapeutics Arvinas Maravai LifeSciences Taysha Gene Therapies Opthea Tyra Biosciences INmune Bio (NASDAQ:INMB) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment. Which has stronger valuation & earnings, INMB or ALT? INmune Bio has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than INmune Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioINmune Bio$10K5,564.88-$42.08M-$1.93-1.22Altimmune$20K19,871.95-$95.06M-$1.26-3.89 Does the media prefer INMB or ALT? In the previous week, INmune Bio had 15 more articles in the media than Altimmune. MarketBeat recorded 37 mentions for INmune Bio and 22 mentions for Altimmune. Altimmune's average media sentiment score of 0.23 beat INmune Bio's score of -0.25 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment INmune Bio 1 Very Positive mention(s) 3 Positive mention(s) 20 Neutral mention(s) 8 Negative mention(s) 1 Very Negative mention(s) Neutral Altimmune 4 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend INMB or ALT? INmune Bio currently has a consensus price target of $18.40, indicating a potential upside of 679.66%. Altimmune has a consensus price target of $19.00, indicating a potential upside of 287.76%. Given INmune Bio's higher possible upside, equities research analysts plainly believe INmune Bio is more favorable than Altimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score INmune Bio 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Altimmune 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in INMB or ALT? 12.7% of INmune Bio shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 35.7% of INmune Bio shares are held by company insiders. Comparatively, 4.1% of Altimmune shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is INMB or ALT more profitable? INmune Bio has a net margin of 0.00% compared to Altimmune's net margin of -451,200.00%. Altimmune's return on equity of -65.44% beat INmune Bio's return on equity.Company Net Margins Return on Equity Return on Assets INmune BioN/A -119.35% -89.37% Altimmune -451,200.00%-65.44%-58.43% Which has more risk and volatility, INMB or ALT? INmune Bio has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. SummaryAltimmune beats INmune Bio on 9 of the 16 factors compared between the two stocks. Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INMB vs. The Competition Export to ExcelMetricINmune BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$49.29M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-1.2221.3126.1719.90Price / Sales5,564.88278.47414.67113.66Price / CashN/A41.4736.1356.90Price / Book1.637.518.055.38Net Income-$42.08M-$55.05M$3.15B$248.50M7 Day Performance-67.98%2.45%1.85%2.97%1 Month Performance-67.18%7.33%4.81%6.02%1 Year Performance-70.76%5.38%34.86%20.39% INmune Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMBINmune Bio1.5849 of 5 stars$2.36+12.9%$18.40+679.7%-75.2%$49.29M$10K-1.2210Trending NewsAnalyst DowngradeHigh Trading VolumeALTAltimmune2.2959 of 5 stars$6.99-0.6%$19.00+171.8%-41.3%$566.94M$20K-5.5550CDTXCidara Therapeutics4.1313 of 5 stars$44.95+113.8%$45.43+1.1%+307.2%$564.12M$1.27M-1.5390Analyst ForecastInsider TradeGap DownHigh Trading VolumeKROSKeros Therapeutics4.1436 of 5 stars$13.76+2.0%$30.56+122.1%-69.5%$558.86M$214.71M-76.44100Positive NewsRLAYRelay Therapeutics3.0479 of 5 stars$3.23+1.3%$17.67+447.0%-45.0%$553.77M$7.68M-1.45330Positive NewsDNTHDianthus Therapeutics1.454 of 5 stars$17.20+2.1%$53.00+208.1%-37.8%$553.15M$6.24M-5.9780News CoverageAnalyst ForecastGap UpARVNArvinas3.7229 of 5 stars$7.40-0.5%$20.29+174.2%-70.6%$540.13M$426.90M-11.21420Positive NewsMRVIMaravai LifeSciences3.6251 of 5 stars$2.11+2.4%$6.64+214.6%-63.8%$537.33M$259.18M-1.85610TSHATaysha Gene Therapies3.3812 of 5 stars$2.49+1.2%$7.57+204.1%+3.5%$534.51M$7.22M-7.32180Analyst ForecastOPTOpthea0.5023 of 5 stars$3.41+7.2%$1.33-60.9%+78.5%$524.83M$120K0.008News CoveragePositive NewsGap UpTYRATyra Biosciences1.9387 of 5 stars$9.71+5.2%$30.83+217.5%-43.8%$515.50MN/A-5.9620News CoverageAnalyst Forecast Related Companies and Tools Related Companies Altimmune Competitors Cidara Therapeutics Competitors Keros Therapeutics Competitors Relay Therapeutics Competitors Dianthus Therapeutics Competitors Arvinas Competitors Maravai LifeSciences Competitors Taysha Gene Therapies Competitors Opthea Competitors Tyra Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INMB) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share INmune Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INMB Stock Alerts